We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old (KL4-AHRF-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00578734
Recruitment Status : Completed
First Posted : December 21, 2007
Results First Posted : April 27, 2012
Last Update Posted : May 3, 2012
Information provided by (Responsible Party):
Windtree Therapeutics

Brief Summary:
Treatment with lucinactant, a peptide-containing synthetic lung surfactant, will be evaluated in young children with acute respiratory failure who require mechanical ventilation (life support), to determine if it is safe and if treatment with lucinactant will reduce the number of days a child needs mechanical ventilation (life support).

Condition or disease Intervention/treatment Phase
Acute Hypoxemic Respiratory Failure Drug: Lucinactant Other: Sham Comparator Phase 2

Detailed Description:
Determine the safety and tolerability of administration of a peptide-containing synthetic lung surfactant, lucinactant, in children up to two years of age and assess whether treatment with lucinactant can decrease the duration of mechanical ventilation in young children.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 165 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Masked, Placebo-Controlled Trial to Assess the Safety and Efficacy of Lucinactant in Acute Hypoxemic Respiratory Failure in Children Up to Two Years of Age
Study Start Date : June 2007
Primary Completion Date : April 2010
Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Lucinactant
SURFAXIN® (lucinactant) for intratracheal instillation
Drug: Lucinactant
Slow intra-tracheal instillation
Other Names:
  • Surfactant
Sham Comparator: Sham Air
Sham air (placebo) instillation
Other: Sham Comparator
Slow intra-tracheal instillation
Other Name: Placebo

Primary Outcome Measures :
  1. Duration of Mechanical Ventilation Through 14 Days [ Time Frame: Up to 14 Days ]
    Duration of mechanical ventilation (MV) from baseline to successful extubation (not receiving MV for at least 24 hours) through a maximum of 14 days.

Secondary Outcome Measures :
  1. Ventilator-free Days; Duration of Days on Oxygen, Intensive Care Unit (ICU) Stay, and Hospitalization Through 14 Days [ Time Frame: Up to 14 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 2 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ≥ 38 weeks (corrected age) to 2 years (24 months)
  • Intubated and mechanically ventilated (MV) for ≥ 6 hours and anticipated need for MV for ≥ 24 hours
  • Persistent hypoxia
  • Written informed consent

Exclusion Criteria:

  • Mechanical Ventilation for > 48 hours
  • Oxygenation index ≥ 25, if arterial line was avialable
  • Pre-existing clinically significant or palliated/uncorrected cardiac disease adversely affecting cardiopulmonary function and gas exchange
  • Neuromuscular disease or hypotonia
  • Upper airway disease
  • Baseline requirment for supplemental oxygen
  • Untreated pneumothorax
  • Off-label use of commercially available surfactant outside neonatal period
  • History of prematurity and passive immunoprophylaxis with humanized monoclonal antibody
  • Head injury with Glasgow Coma Scale < 8
  • Brain death or impending brain death
  • Do not resuscitate orders
  • Cardiopulmonary resuscitation within 6 hours of meeting entry criteria
  • Experimental therapy in which the intervention potentially affects respiratory outcomes
  • Any transplant recipient
  • Meconium aspiration syndrome
  • Bordetella pertussis infection confirmed via laboratory tests and/or highly suspected pertussis infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00578734

United States, Pennsylvania
Call for information
Warrington, Pennsylvania, United States, 18976
Call for Information
Concepcion, Chile
Call For Information
Santiago, Chile
Sponsors and Collaborators
Windtree Therapeutics
Principal Investigator: Neal Thomas, MD Milton S. Hershey Medical Center
Principal Investigator: Adrienne Randolph, MD Boston Children’s Hospital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Windtree Therapeutics
ClinicalTrials.gov Identifier: NCT00578734     History of Changes
Other Study ID Numbers: KL4-AHRF-01
First Posted: December 21, 2007    Key Record Dates
Results First Posted: April 27, 2012
Last Update Posted: May 3, 2012
Last Verified: May 2012

Additional relevant MeSH terms:
Respiratory Insufficiency
Respiration Disorders
Respiratory Tract Diseases